Chinook Therapeutics (NASDAQ:KDNY) Issues Earnings Results, Misses Estimates By $0.82 EPS


Share on StockTwits

Chinook Therapeutics (NASDAQ:KDNY) announced its quarterly earnings data on Tuesday. The company reported ($1.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.82), MarketWatch Earnings reports. Chinook Therapeutics had a negative net margin of 215.80% and a negative return on equity of 112.72%.

NASDAQ KDNY opened at $14.75 on Thursday. The business’s fifty day moving average price is $16.88. The company has a market cap of $621.83 million, a P/E ratio of -4.10 and a beta of 0.26. Chinook Therapeutics has a 1 year low of $10.50 and a 1 year high of $21.68.

A number of brokerages recently commented on KDNY. Zacks Investment Research raised shares of Chinook Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, January 11th. Cantor Fitzgerald assumed coverage on shares of Chinook Therapeutics in a research report on Wednesday, December 9th. They issued an “overweight” rating and a $31.00 target price for the company. Bloom Burton reissued a “buy” rating on shares of Chinook Therapeutics in a research report on Monday, March 22nd. Finally, Wedbush assumed coverage on shares of Chinook Therapeutics in a research report on Wednesday, January 6th. They issued an “outperform” rating and a $28.00 target price for the company. One investment analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $28.29.

About Chinook Therapeutics

Chinook Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, an investigational Phase III ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases.

Further Reading: Candlestick

Earnings History for Chinook Therapeutics (NASDAQ:KDNY)

Receive News & Ratings for Chinook Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chinook Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.